Trial Profile
An Open-Label Long-Term Study of the Safety and Tolerability of Repeated administration of CEP-33457 in Patients With Systemic Lupus Erythematosus
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Forigerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms Celestial 75
- Sponsors Cephalon; Teva Pharmaceutical Industries
- 09 Apr 2022 According to European Clinical Trials Database, the trial is completed in Spain (2012-06-14)
- 20 Mar 2014 New trial record